OXURION NV – First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME)

NEXT STORY
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
PREV STORY
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medical Prognosis Institute publishes selected financial information for the period 1 July 2017 – 31 December 2017 due to the proposed merger between Medical Prognosis Institute and Oncology Venture

Hørsholm, Denmark - Medical Prognosis Institute A/S ("MPI") (Nasdaq First North Stockholm: MPI) today ...

author_avatar
NASDAQ Market News

Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights

author_avatar
NASDAQ Market News

Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases

UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology ...

author_avatar
NASDAQ Market News